Virios Therapeutics, Inc. (VIRI)

0.4626 -0.0156 (-3.26%) As of 11:26AM EDT. Market open.

Virios Therapeutics, Inc.

44 Milton Avenue
Alpharetta, GA 30009
United States
866 620 8655
https://www.virios.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gregory Duncan	Chairman & CEO	559.59k	N/A	1966
Dr. William L. Pridgen M.D.	Founder & Director	35k	N/A	1961
Ms. Angela Walsh	CFO, SVP of Finance, Corporate Secretary & Treasurer	281.28k	N/A	1967
Dr. R. Michael Gendreau M.D., Ph.D.	Chief Medical Officer	420.64k	N/A	1956
Mr. Ralph D. Grosswald M.P.H.	Senior Vice President of Operations	274.69k	N/A	1969
Ms. Carol Duffy Ph.D.	Chief Scientific Advisor	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Virios Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.